Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivastigmine for ECT-induced interictal delirium in late-life depression
NL-OMON23967Recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Sep 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of rivastigmine in major depressive disorder (MDD) (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoints: Delirium severity and Cognitive functioning. Started Sep 2017; status: recruiting.
02
Drugs
rivastigmine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NL-OMON23967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON23967.